By Monica Heger

This story, originally published Aug. 16, has been updated to clarify information about the performance of the company's tests.

Pathogen sequencing company Pathogenica is developing its first product — a sequencing-based diagnostic for human papillomavirus — which it expects to launch in 2012 as a US Food and Drug Administration-approved kit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.